1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion

Jean Yves Blay; H. Gelderblom; P. Rutkowski; A. Wagner; Meike van de Sande; A. Falcon Gonzalez; S. Stacchiotti; A. Le Cesne; T. Alcindor; C. Serrano; E. Palmerini; Vishnu Ravi; A. Casado Herráez; B. Seddon; Michael F. Vallee; R. Jarecha; M. Sharma; R. Ruiz-Soto; M.L. Sherman; W.D. Tap

doi:10.1016/j.annonc.2022.07.1612

Related publications

Article2022

P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study

Jean Yves Blay, Hans Gelderblom, P Rutkowski, AJ Wagner, M van de Sande, Silvia Stacchiotti, Axel Le Cesne, E Palmerini, Marc Vallee, B. Harrow, Christoph R. Becker, Rudresh Jarecha, Maitreyi G. Sharma, W.D. Tap

Article2025

2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial

Sebastian Bauer, Vivek A. Bhadri, H. Gelderblom, S. Stacchiotti, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, A. Le Cesne, Christopher Tait, Fiona Zarins, N. Zeringo, B. Harrow, Manu Sharma, M.L. Sherman, Jean Yves Blay, W.D. Tap

Article2024

LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

H. Gelderblom, Vivek A. Bhadri, S. Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Meike van de Sande, Nicholas M. Bernthal, Albiruni Ryan Abdul Razak, A. Italiano, M. Ahmed, Axel Le Cesne, Christopher Tait, A. Saunders, B. Harrow, Manu Sharma, R. Ruiz-Soto, M.L. Sherman, Jean Yves Blay, W.D. Tap

Article2024

1769P Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

C. Serrano, Jean Yves Blay, P. Rutkowski, Hans Gelderblom, S. Stacchiotti, A. Falcon Gonzalez, Janak Desai, A. Le Cesne, Virginia Ferraresi, E. Palmerini, Breelyn A. Wilky, Andrew J. Wagner, Nicholas M. Bernthal, Michiel A. J. van de Sande, Supraja Narasimhan, B. Harrow, Manu Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap

Article2024

Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.

William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom

1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion

Discussion(0)

Related publications

P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study

2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial

LBA78 Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

1769P Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.